USA: Melatonin Use Linked to Reduced Risk for Development, Progression of AMD

Melatonin use is associated with a reduced risk for development and progression of age-related macular degeneration (AMD), according to a study published online June 6 in JAMA Ophthalmology.

Hejin Jeong, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues conducted a retrospective cohort study to examine the association between melatonin supplementation and the risk for development or progression of AMD. Melatonin medication codes were queried for patients aged 50 years or older, 60 years or older, and 70 years or older with no history of AMD (AMD-naive group) and with a history of nonexudative AMD (nonexudative AMD group). Based on the presence of medication codes for melatonin, patients were then classified into a melatonin group or control group.

Source: Advances and More licensed by HealthDay